Preneoplastic lesions in human hepatocarcinogenesis

Liver International

Volumn 25, Issue 1, 2005, Pages 16-27

  Libbrecht, Louis ^a   Desmet, Valeer ^a   Roskams, Tania ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL;

CANCER DIAGNOSIS; CANCER RISK; CELL DIFFERENTIATION; CHRONIC LIVER DISEASE; CLONAL VARIATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DYSPLASIA; ECHOGRAPHY; EPIGENETICS; GENE MUTATION; GENETIC POLYMORPHISM; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER NODULE; LIVER RESECTION; LIVER TRANSPLANTATION; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRECANCER; PREDICTION; REVIEW; RISK FACTOR; TUMOR DIFFERENTIATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; PRECANCEROUS CONDITIONS;

EID: 14544292426     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01016.x     Document Type: Review

References (102)

1. Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Russo M W, Wei J T, Thiny M T, et al. Digestive and liver disease statistics, 2004. Gastroenterology 2004; 126: 1448-53.
3. Yeh S H, Chen P J, Shau W Y, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001; 121: 699-709.
4. Inoue H, Seitz H K. Viruses and alcohol in the pathogenesis of primary hepatic carcinoma. European J Cancer Prevent 2001; 10: 107-10.
5. Macarthur M, Hold G L, El-Omar E M. Inflammation and cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointestinal Liver Physiol 2004; 286: G515-20.
6. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120: 1763-73.
7. Feitelson M A, Sun B, Tufan N L S, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21: 2593-604.
8. Pitot H C. Pathways of progression in hepatocarcinogenesis. Lancet 2001; 358: 859-60.
9. Chen X, Cheung S T, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13: 1929-39.
10. Saeki R, Nagai H, Kaneko S, et al. Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning. J of Hepatol 2000; 33: 99-105.
11. Su Q, Benner A, Hofmann W J, et al. Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Archiv 1997; 431: 391-406.
12. Borzio M, Roncalli M, Trere D, et al. Preneoplastic cellular changes in liver. Hepatology 1998; 28: 1435-6.
13. Libbrecht L, Craninx M, Nevens F, et al. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001; 39: 66-73.
14. Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
15. Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39: 208-14.
16. Watanabe S, Okita K, Harada T, et al. Morphologic studies of the liver-cell dysplasia. Cancer 1983; 51: 2197-205.
17. Anthony P P, Vogel C L, Barker L F. Liver cell dysplasia: a premalignant condition. J Clin Pathol 1973; 26: 217-23.
18. Le Bail B, Bernard P H, Carles J, et al. Prevalence of liver cell dysplasia and association with HCC in a series of 100 cirrhotic liver explants. J Hepatol 1997; 27: 835-42.
19. Blanc J F, De Ledinghen V, Trimoulet P, et al. Premalignant lesions and hepatocellular carcinoma in a non-cirrhotic alcoholic patient with iron overload and normal transferrin saturation. J Hepatol 1999; 30: 325-9.
20. Marchio A, Terris B, Meddeb M, et al. Chromosomal abnormalities in liver cell dysplasia detected by comparative genomic hybridisation. J Clin Pathol-Mol Pathol 2001; 54: 270-4.
21. Libbrecht L, Desmet V, Van Damme B, et al. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. J Hepatol 2000; 33: 70-84.
22. Libbrecht L, De Vos R, Cassiman D, et al. Hepatic progenitor cells in hepatocellular adenomas. Am J Surg Pathol 2001; 25: 1388-96.
23. Dumble M L, Croager E J, Yeoh G C T, et al. Generation and characterization of p53 null transformed hepatic progenitor cells: oval cells give rise to hepatocellular carcinoma. Carcinogenesis 2002; 23: 435-45.
24. Libbrecht L, Roskams T. Hepatic progenitor cells in human liver diseases. Semin Cell Dev Biol 2002; 13: 389-96.
25. Roncalli M, Borzio M, Brando B, et al. Abnormal DNA content in liver cell dysplasia - a flow cytometric study. Int J Cancer 1989; 44: 204-7.
26. Thomas R M, Berman J J, Yetter R A, et al. Liver cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Human Pathol 1992; 23: 496-503.
27. Lee R G, Tsamandas A C, Demetris A J. Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997; 26: 1415-22.
28. Santoni-Rugiu E, Nagy P, Jensen M R, et al. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha. Am J Pathol 1996; 149: 407-28.
29. Libbrecht L, Desmet V, Van Damme B, et al. The expression of p16 in liver cell dysplasia in human cirrhotic liver. European J Cancer Prevent 2000; 9: 444.
30. Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. update and diagnostic problems. Mod Pathol 2000; 13: 679-704.
31. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis - a prospective study. Gastroenterology 1995; 108: 812-7.
32. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology 1996; 23: 1112-8.
33. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-6.
34. Donato M F, Arosio E, Del Ninno E, et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2001; 34: 523-8.
35. Eguchi A, Nakashima O, Okudaira S, et al. Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 1992; 15: 843-8.
36. Kaji K, Terada T, Nakanuma Y. Frequent occurrence of hepatocellular carcinoma in cirrhotic livers after surgical resection of atypical adenomatous hyperplasia (borderline hepatocellular lesion) - a follow-up study. Am J Gastroenterol 1994; 89: 903-8.
37. Arakawa M, Kage M, Sugihara S, et al. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver - observations in 5 cases. Gastroenterology 1986; 91: 198-208.
38. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990; 336: 1150-3.
39. International Working Party. Terminology of hepatocellular nodular lesions. Gastroenterology 1995; 22: 983-93.
40. Maggioni M, Coggi G, Cassani B, et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies. Hepatology 2000; 32: 942-6.
41. Sun M, Eshleman J R, Ferrell L D, et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001; 33: 1415-24.
42. Tornillo L, Carafa V, Sauter G, et al. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: high-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest 2002; 82: 547-53.
43. Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications for diagnosis and classification. Hepatology 1999; 30: 1174-8.
44. Seki S, Sakaguchi H, Kitada T, et al. Outcomes of dysplastic nodules in human cirrhotic liver: a clinicopathological study. Clin Cancer Res 2000; 6: 3469-73.
45. Lencioni R, Caramella D, Bartolozzi C, et al. Percutaneous ethanol injection therapy of adenomatous hyperplastic nodules in cirrhotic liver disease. Acta Radiol 1994; 35: 138-42.
46. Ishikawa M, Yogita S, Miyake H, et al. Differential diagnosis of small hepatocellular carcinoma and borderline lesions and therapeutic strategy. Hepato-Gastroenterology 2002; 49: 1591-6.
47. Burell M, Llovet J M, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-42.
48. Krinsky GA, Lee VS, Theise ND, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transplant 2002; 8: 1156-64.
49. Libbrecht L, Bielen D, Verslype C, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transplant 2002; 8: 749-61.
50. De Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. European J Gastroenterol Hepatol 2002; 14: 159-65.
51. Quaglia A, Tibballs J, Grasso A, et al. Focal nodular hyperplasia-like areas in cirrhosis. Histopathology 2003; 42: 14-21.
52. Verslype C, Libbrecht L, Nevens F, et al. Relevance of detecting additional small HCC lesions prior to liver transplantation. J Hepatol 2003; 38: 51.
53. Hayashi P H, Steinberg T, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transplant 2004; 10: 42-8.
54. Llovet J M, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transplant 2004; 10: 115-20.
55. Huang G T, Sheu J C, Yang P M, et al. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma - A study based on 420 patients. J Hepatol 1996; 25: 334-8.
56. Quaglia A, Bhattacharjya S, Dhillon A P. Limitations of the histopathogical diagnosis and prognostic assessment of hepatocellular carcinoma. Histopathology 2001; 38: 167-74.
57. Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transplant 2004; 2004: 9-15.
58. Ryder S D. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52: 1-8.
59. Bruix J, Sherman M, Llovet J M, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35: 421-30.
60. Caturelli E, Ghittoni G, Roselli P, et al. Fine needle biopsy of focal liver lesions: the hepatologist's point of view. Liver Transplant 2004; 10: 26-9.
61. Torzilli G, Olivari N, Del Fabbro D, et al. Indication and contraindication for hepatic resection for liver tumors without fine-needle biopsy: validation and extension of an Eastern approach in a Western community hospital. Liver Transplant 2004; 10: 30-3.
62. Paradis V, Bieche I, Dargere D, et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach - Determination of a molecular diagnostic index. Am J Pathol 2003; 163: 733-41.
63. Quaglia A, Dhillon A, Colombari R, et al. A novel scoring sytem. for the histological diagnosis of hepatocellular carcinoma in cirrhotic liver. J Hepatol 2001; 34: 105.
64. Hytiroglou P, Kotoula V, Thung S N, et al. Telomerase activity in precancerous hepatic nodules. Cancer 1998; 82: 1831-8.
65. Oh B K, Chae K J, Park C, et al. Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis. J Hepatol 2003; 39: 786-92.
66. Millward-Sadler G H. Liver cirrhosis. In: MacSween R N M, Anthony P P, Scheuler P J, Burt A D, Portmann B C, eds. Pathology of the Liver. Edinburgh: Churchill-Livingstone, 1994; 397-424.
67. Aihara T, Noguchi S, Sasaki Y, et al. Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 1994; 107: 1805-11.
68. Paradis V, Laurendeau I, Vidaud M, et al. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28: 953-8.
69. Diallo R, Schaefer K L, Poremba C, et al. Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol 2001; 193: 27-32.
70. Shiojiri N, Sano M, Inujima S, et al. Quantitative analysis of cell allocation during liver development, using the spf(ash)-heterozygous female mouse. Am J Pathol 2000; 156: 65-75.
71. Ochiai T, Urata Y, Yamano T, et al. Clonal expansion in evolution of chronic hepatitis to hepatocellular carcinoma as seen at an X-chromosome locus. Hepatology 2000; 31: 615-21.
72. Tiniakos D G, Brunt E M. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 1999; 19: 58-68.
73. Anders R A, Yerian L M, Tretiakova M, et al. cDNA microarray analysis of macroregenerative and dysplastic nodules in end-stage hepatitis C virus-induced cirrhosis. Am J Pathol 2003; 162: 991-1000.
74. Colombat M, Paradis V, Bieche I, et al. Quantitative RT-PCR in cirrhotic nodules reveals gene expression changes associated with liver carcinogenesis. J Pathol 2003; 201: 260-7.
75. Roncalli M, Bianchi P, Grimaldi G C, et al. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up. Hepatology 2000; 31: 846-50.
76. Hirota N, Hamazaki M, Williams G M. Resistance to iron accumulation and presence of hepatitis B surface antigen in preneoplastic and neoplastic lesions in human hemochromatotic livers. Hepato-Gastroenterology 1982; 29: 49-51.
77. Deugnier Y M, Charalambous P, Lequilleuc D, et al. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis - a study of 185 patients. Hepatology 1993; 18: 1363-9.
78. Libbrecht L, Meerman L, Kuipers F, et al. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 2003; 199: 191-200.
79. Guyader D, Gandon Y, Sapey T, et al. Magnetic resonance iron-free nodules in genetic hemochromatosis. Am J Gastroenterol 1999; 94: 1083-6.
80. Krinsky G A, Lee V S, Nguyen M T, et al. Siderotic nodules in the cirrhotic liver at MR imaging with explant correlation: no increased frequency of dysplastic nodules and hepatocellular carcinoma. Radiology 2001; 218: 47-53.
81. Lefkowitch J H, Yee H T, Sweeting J, et al. Iron-rich foci in chronic viral hepatitis. Human Pathol 1998; 29: 116-8.
82. Hytiroglou P. Morphological changes of early human hepatocarcinogenesis. Semin Liver Dis 2004; 24: 65-75.
83. Krinsky G A, Lee V S, Nguyen M T, et al. Siderotic nodules at MR imaging: regenerative or dysplastic? J Comput Assist Tomogr 2000; 24: 773-6.
84. Terada T, Kadoya M, Nakanuma Y, et al. Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 1990; 65: 1994-2000.
85. Shuto T, Hirohashi K, Wakasa K, et al. Hyperplastic foci as a prognostic factor after resection of hepatocellular carcinoma. Hepato-Gastroenterology 1999; 46: 2439-41.
86. Kato K, Ozaki D, Zheng K F, et al. Characterization of hyperplastic foci observed in surgical specimens of hepatocellular carcinoma. Pathol Int 2001; 51: 20-5.
87. Shibata M, Morizane T, Uchida T, et al. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet 1998; 351: 1773-7.
88. Bannasch P, Klimek F, Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 1997; 29: 303-13.
89. Lefkowitch J H, Arborgh B A M, Scheuer P J. Oxyphilic granular hepatocytes - mitochondrion-rich liver cells in hepatic disease. Am J Clin Pathol 1980; 74: 432-41.
90. Dombrowski F, Bannasch P, Pfeifer U. Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol 1997; 150: 1071-87.
91. Chang A, Harawi S J. Oncocytes, oncocytosis, and oncocytic tumors. Pathol Annu 1992; 27: 263-304.
92. Muller-Hocker J, Aust D, Rohrbach H, et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology 1997; 26: 709-19.
93. Mandel H, Hartman C, Berkowitz D, et al. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001; 34: 776-84.
94. Tanji K, Bhagat G, Vu T H, et al. Mitochondrial DNA dysfunction in oncocytic hepatocytes. Liver Int 2003; 23: 397-403.
95. Klotz L, Hacker H J, Klingmuller D, et al. Hepatocellular alterations after intraportal transplantation of ovarian tissue in ovariectomized rats. Am J Pathol 2000; 156: 1613-26.
96. Sola J, Pardomindan FJ, Zozaya J, et al. Liver changes in patients with hyperthyroidism. Liver 1991; 11: 193-7.
97. Bayraktar M, VanThiel D H. Abnormalities in measures of liver function and injury in thyroid disorders. HepatoGastroenterology 1997; 44: 1614-8.
98. Grisham J W. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 1997; 18: 59-81.
99. Factor V M, Laskowska D, Jensen M R, et al. Vitamin E reduces chromosomal damage and inhibits hepatic tumor formation in a transgenic mouse model. Proc Natl Acad Sci USA 2000; 97: 2196-201.
100. Murata M, Miyoshi Y, Ohsawa M, et al. Accumulation of beta-catenin in the cytoplasm and the nuclei during the early hepatic tumorigenesis. Hepatol Res 2001; 21: 126-35.
101. Harada N, Oshima H, Katoh M, et al. Hepatocarcinogenesis in mice with beta-catenin and Ha-Ras gene mutations. Cancer Res 2004; 64: 48-54.
102. Calvisi D F, Factor V M, Ladu S, et al. Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice. Gastroenterology 2004; 126: 1374-86.